FDA’s June 2024 list of off-patent, off-exclusivity drugs sees rise in cancer, HIV treatments
This week PharmaCompass brings to you key highlights of the US Food and Drug Administration’s
Top drugs and pharmaceutical companies of 2019 by revenues
Acquisitions and spin-offs dominated headlines in 2019 and the tone was set very early with Bristol-
2017 – Recap of Warning Letters, Import Alerts and Non-Compliances
Data
integrity continued to be a hot topic in the pharmaceutical industry through
2017. According to
Pharma Deals, Investments and M&As in September 2017
In our continuous endeavor to share business intelligence that can help grow your pharmaceutical bus
Mid-2017 Recap of FDA Warning Letters, Import Alerts & EU Non-Compliances
Last year, data
integrity was a hot topic of discussion in the pharmaceutical industry.
According t
FDA problems at Pfizer’s US facility continue; China FDA joins ICH
This week in our compliance round up, we look at the continuing problems at Pfizer’s McPherson